Emcure Pharma, BHEL, Fractal Analytics among buzzing stocks; SENSEX recovers 400 pts, NIFTY above 23,850
Zydus Lifesciences stock declined as much as 4.7% to reach the session’s low of ₹1,182.40 per equity share on the NSE, as it saw its consolidated net profit fall 26.57% YoY to ₹926 crore in Q2 FY27, compared with ₹1,261 crore in the year-ago period.
Zydus Lifesciences stock declined as much as 4.7% to reach the session’s low of ₹1,182.40 per equity share on the NSE, as it saw its consolidated net profit fall 26.57% YoY to ₹926 crore in Q2 FY27, compared with ₹1,261 crore in the year-ago period.
What's Your Reaction?
